A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental study, pharmacological inhibition of an enzyme that plays a central role in ...
It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...
Liver cancer rates have more than tripled in the U.S. since 1980 and continue to rise. More than 41,000 people will be ...
Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug in combination with atezolizumab and bevacizumab in patients with unresectable, ...
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...
7d
Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...
Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...
About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...
A toxin in the bacteria that's one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of the body, a study led by UF Health Cancer Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback